Close Menu

Imexpharm increases its presence at international markets

With Globalization strategy to reach out to the international market, Imexpharm Pharmaceutical Joint Stock Company participated in the CPHI Event in Barcelona, Spain from 24th to 26th October. CPHI is an annual event that connects the leading pharmaceutical manufacturers worldwide to exchange technological innovations, new products, to find partners and connect global supply chains…etc.

CPHI event in Barcelona, Spain

At this event, Imexpharm had a booth to introduce products, especially important antibiotic ones, and Imexpharm's production innovations to international partners. At the same time, Imexpharm also has activities to meet foreign partners to seek opportunities for cooperation and market expansion.

As part of its Globalization strategy, Imexpharm has not only increased its presence in the international market but also assessed the current state of its quality control system (QCS) according to the cGMP standard, a stringent pharmaceutical safety assessment standard issued by the United States Food and Drug Administration (FDA). This is a mandatory standard for pharmaceutical manufacturers exporting products to the US market.


Imexpharm Team in CPHI event

Established in 1977, over nearly half of century, Imexpharm has always set the goal of improving product quality to provide the domestic and international markets with high-quality, reliable, and effective pharmaceutical products to community in health care activities. Currently, Imexpharm owns 3 EU-GMP factories clusters with 11 production lines that also meet the EU-GMP standard, including Vinh Loc high-tech antibiotic factory (IMP2), Binh Duong, Betalactam antibiotic factory (IMP3), and Binh Duong high-tech factory (IMP4).

Customer visits Imexpharm booth

Currently, Imexpharm is also a partner with many leading global pharmaceutical manufacturers, including Sandoz, Robinson Pharma, DP Pharma, Galien, Pharmacien Canada, and Sanofi-Aventis. Moreover, Imexpharm has been constantly upgrading technology with modern technical infrastructure, optimizing production processes and human resources to provide quality products and services. By the end of 2022, Imexpharm has 12 registration numbers for 7 products in Europe.